{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:25:44Z","timestamp":1790727944491,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Polish Mother's Memorial Hospital Research Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose of Review<\/jats:title>\n<jats:p>We aimed to summarize recent guidelines, position papers, and high-quality clinical research relating the use of nutraceuticals in the management of individuals at high risk of atherosclerotic cardiovascular disease.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Recent Findings<\/jats:title>\n<jats:p>It is essential that individuals at high risk of cardiovascular disease receive guideline-directed evidence-based therapies to reduce their risk of morbidity and mortality from cardiovascular events. Compared with conventional therapeutics, nutraceuticals have undergone relatively little investigation in randomized controlled trials. Thus, recommendations for nutraceuticals in international guidelines are rare, and nutraceuticals should not be used preferentially in place of statins. Nevertheless, recent position papers from the International Lipid Expert Panel and clinical evidence from studies of triglyceride reduction by polyunsaturated fatty acid administration demonstrate that nutraceuticals do have an important role in optimizing therapy in individuals at high risk of cardiovascular disease. Roles for nutraceuticals include as follows: (1) managing residual risk associated with lipids other than low-density lipoprotein cholesterol (LDL-C); (2) managing non-lipid-mediated residual risk; (3) optimizing LDL-C treatment in statin intolerance; (4) optimizing LCL-C treatment when add-on therapies for statins are not available; (5) as adjuncts to lifestyle for individuals at high lifetime risk of atherosclerotic cardiovascular disease (ASCVD). The strength of evidence for each of these applications is variable.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Summary<\/jats:title>\n<jats:p>In addition to guideline-directed therapeutics, nutraceuticals may have roles in optimizing preventative therapy and targeting residual risk in individuals at high risk of ASCVD. Application of Good Manufacturing Practice and randomized controlled trials when producing and evaluating nutraceuticals will expand the armoury of evidence-based agents for the prevention of ASCVD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s11883-020-00887-z","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T05:02:58Z","timestamp":1600405378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia"],"prefix":"10.1007","volume":"22","author":[{"given":"Peter E.","family":"Penson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"issue":"Suppl 1","key":"887_CR1","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.21037\/cdt.2017.03.20.","volume":"7","author":"B Sosnowska","year":"2017","unstructured":"Sosnowska B, Penson P, Banach M. The role of nutraceuticals in the prevention of cardiovascular disease. Cardiovasc Diagn Ther. 2017;7(Suppl 1):S21\u201331. https:\/\/doi.org\/10.21037\/cdt.2017.03.20.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"2","key":"887_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0924-2244(00)88944-X","volume":"6","author":"SL DeFelice","year":"1995","unstructured":"DeFelice SL. The nutraceutical revolution - its impact on food-industry R-and-D. Trends Food Sci Technol. 1995;6(2):59\u201361. https:\/\/doi.org\/10.1016\/S0924-2244(00)88944-X.","journal-title":"Trends Food Sci Technol"},{"key":"887_CR3","doi-asserted-by":"crossref","unstructured":"Mazza G Functional foods: biochemical and processing aspects. CRCs; 1998.","DOI":"10.1201\/9781482278736"},{"key":"887_CR4","unstructured":"World Health Organization. World Health Statistics 2018: monitoring health for the SDGs 2018."},{"issue":"4","key":"887_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/01.cir.34.4.679","volume":"34","author":"JW Gofman","year":"1966","unstructured":"Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation. 1966;34(4):679\u201397. https:\/\/doi.org\/10.1161\/01.cir.34.4.679.","journal-title":"Circulation."},{"issue":"18","key":"887_CR6","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.cir.97.18.1837","volume":"97","author":"PW Wilson","year":"1998","unstructured":"Wilson PW, D\u2019Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837\u201347. https:\/\/doi.org\/10.1161\/01.cir.97.18.1837.","journal-title":"Circulation."},{"issue":"1","key":"887_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. https:\/\/doi.org\/10.1038\/s41572-019-0106-z.","journal-title":"Nat Rev Dis Primers"},{"key":"887_CR8","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020. https:\/\/doi.org\/10.1093\/eurheartj\/ehz962This paper provides an excellent and comprehensive overview of the physiological mechanisms relating LDL-C to ASCVD and how these can be targetted therapeutically.","DOI":"10.1093\/eurheartj\/ehz962"},{"issue":"32","key":"887_CR9","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"\u2022\u2022 Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144This paper provides an excellent and comprehensive overview of the epidemiological evidence linking LDL-C to ASCVD.","journal-title":"Eur Heart J"},{"issue":"10","key":"887_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","volume":"318","author":"BA Ference","year":"2017","unstructured":"Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA. 2017;318(10):947\u201356. https:\/\/doi.org\/10.1001\/jama.2017.11467.","journal-title":"JAMA."},{"issue":"10059","key":"887_CR11","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(16)31357-5.","journal-title":"Lancet."},{"issue":"3","key":"887_CR12","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/cvr\/cvy301","volume":"115","author":"M Banach","year":"2019","unstructured":"Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Cardiovasc Res. 2019;115(3):e26\u201331. https:\/\/doi.org\/10.1093\/cvr\/cvy301.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"887_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","volume":"14","author":"K Dyrbus","year":"2020","unstructured":"Dyrbus K, Gasior M, Penson P, Ray KK, Banach M. Inclisiran-new hope in the management of lipid disorders? J Clin Lipidol. 2020;14(1):16\u201327. https:\/\/doi.org\/10.1016\/j.jacl.2019.11.001.","journal-title":"J Clin Lipidol"},{"issue":"25","key":"887_CR14","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"key":"887_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jamacardio.2019.2306","volume":"4","author":"RG Bach","year":"2019","unstructured":"Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, et al. Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2019;4:846\u201354. https:\/\/doi.org\/10.1001\/jamacardio.2019.2306.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"887_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/13543784.2017.1280458","volume":"26","author":"P Penson","year":"2017","unstructured":"Penson P, McGowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opin Investig Drugs. 2017;26(2):251\u20139. https:\/\/doi.org\/10.1080\/13543784.2017.1280458.","journal-title":"Expert Opin Investig Drugs"},{"issue":"22","key":"887_CR17","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","volume":"73","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791\u2013802. https:\/\/doi.org\/10.1016\/j.jacc.2019.02.032.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"887_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"key":"887_CR19","doi-asserted-by":"publisher","first-page":"CD003177","DOI":"10.1002\/14651858.CD003177.pub5","volume":"3","author":"AS Abdelhamid","year":"2020","unstructured":"Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3:CD003177. https:\/\/doi.org\/10.1002\/14651858.CD003177.pub5.","journal-title":"Cochrane Database Syst Rev"},{"key":"887_CR20","doi-asserted-by":"publisher","first-page":"19188","DOI":"10.1038\/srep19188","volume":"6","author":"MC Serban","year":"2016","unstructured":"Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Jones SR, Muntner P, et al. Impact of L-carnitine on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2016;6:19188. https:\/\/doi.org\/10.1038\/srep19188.","journal-title":"Sci Rep"},{"key":"887_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.phrs.2016.01.030","volume":"105","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar A, Simental-Mendia LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis. Pharmacol Res. 2016;105:198\u2013209. https:\/\/doi.org\/10.1016\/j.phrs.2016.01.030.","journal-title":"Pharmacol Res"},{"issue":"9","key":"887_CR22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/nutrit\/nux047","volume":"75","author":"AFG Cicero","year":"2017","unstructured":"Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutr Rev. 2017;75(9):731\u201367. https:\/\/doi.org\/10.1093\/nutrit\/nux047.","journal-title":"Nutr Rev"},{"issue":"5","key":"887_CR23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.5114\/aoms.2017.69326","volume":"13","author":"AFG Cicero","year":"2017","unstructured":"Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, et al. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci. 2017;13(5):965\u20131005. https:\/\/doi.org\/10.5114\/aoms.2017.69326.","journal-title":"Arch Med Sci"},{"issue":"1","key":"887_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","volume":"72","author":"M Banach","year":"2018","unstructured":"\u2022\u2022 Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72(1):96\u2013118. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.040This important document summarizes the evidence relating to the use of nutraceuticals in statin intolerance and offers practical treatment advice.","journal-title":"J Am Coll Cardiol"},{"key":"887_CR25","doi-asserted-by":"crossref","unstructured":"Bartlomiejczyk M, Penson PE, Banach M. Vitamin D and SAMS. In: P.D. T, Taylor B, editors. Statin-associated muscle symptoms. Springer Nature; 2020. p. 121\u20138.","DOI":"10.1007\/978-3-030-33304-1_14"},{"key":"887_CR26","doi-asserted-by":"crossref","unstructured":"Zaleski AL. Coenzyme Q10 and SAMS. In: P.D. T, Taylor B, editors. Statin-associated muscle symptoms. Springer Nature; 2020. p. 129\u201335.","DOI":"10.1007\/978-3-030-33304-1_15"},{"key":"887_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.003","volume":"24","author":"V Barrios","year":"2017","unstructured":"Barrios V, Escobar C, Cicero AF, Burke D, Fasching P, Banach M, et al. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: review of the clinical evidence. Atheroscler Suppl. 2017;24:1\u201315. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2016.10.003.","journal-title":"Atheroscler Suppl"},{"key":"887_CR28","doi-asserted-by":"crossref","unstructured":"Penson PE, Pirro M, Banach M, International Lipid Expert Panel. LDL-C: lower is better for longer \u2013 even at low risk. BMC Medicine. 2020;*In press.","DOI":"10.1186\/s12916-020-01792-7"},{"issue":"1","key":"887_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-018-0740-x","volume":"17","author":"LL O\u2019Mahoney","year":"2018","unstructured":"O\u2019Mahoney LL, Matu J, Price OJ, Birch KM, Ajjan RA, Farrar D, et al. Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. Cardiovasc Diabetol. 2018;17(1):98. https:\/\/doi.org\/10.1186\/s12933-018-0740-x.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"887_CR30","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.3390\/nu7042085","volume":"7","author":"YS Kim","year":"2015","unstructured":"Kim YS, Xun P, He K. Fish consumption, long-chain omega-3 polyunsaturated fatty acid intake and risk of metabolic syndrome: a meta-analysis. Nutrients. 2015;7(4):2085\u2013100. https:\/\/doi.org\/10.3390\/nu7042085.","journal-title":"Nutrients."},{"key":"887_CR31","doi-asserted-by":"publisher","unstructured":"Mason RP. New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease. Curr Atheroscler Rep. 2019;21(1). 2 https:\/\/doi.org\/10.1007\/s11883-019-0762-1.","DOI":"10.1007\/s11883-019-0762-1"},{"issue":"21","key":"887_CR32","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/01.cir.0000038493.65177.94","volume":"106","author":"PM Kris-Etherton","year":"2002","unstructured":"Kris-Etherton PM, Harris WS, Appel LJ. American Heart Association. Nutrition C. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747\u201357. https:\/\/doi.org\/10.1161\/01.cir.0000038493.65177.94.","journal-title":"Circulation."},{"issue":"16","key":"887_CR33","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"Group ASC, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1804989.","journal-title":"N Engl J Med"},{"issue":"1","key":"887_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1811403.","journal-title":"N Engl J Med"},{"issue":"10","key":"887_CR35","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/clc.23055","volume":"41","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41(10):1281\u20138. https:\/\/doi.org\/10.1002\/clc.23055.","journal-title":"Clin Cardiol"},{"key":"887_CR36","unstructured":"AstraZeneca PLC. Update on phase III STRENGTH trial for Epanova in mixed dyslipidaemia 13\/1\/20. 2020. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html."},{"key":"887_CR37","doi-asserted-by":"publisher","unstructured":"Mazidi M, Mikhailidis DP, Banach M. Omega-3 fatty acids and risk of cardiovascular disease: systematic review and meta-analysis of randomized controlled trials with 127,447 individuals and a Mendelian randomization study. Circulation. 2019;140:e965\u2013e1011. https:\/\/doi.org\/10.1161\/CIR.0000000000000742.","DOI":"10.1161\/CIR.0000000000000742"},{"issue":"6","key":"887_CR38","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/10408363.2016.1188055","volume":"53","author":"K Kotani","year":"2016","unstructured":"Kotani K, Serban MC, Penson P, Lippi G, Banach M. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - some answers and still many questions. Crit Rev Clin Lab Sci. 2016;53(6):370\u20138. https:\/\/doi.org\/10.1080\/10408363.2016.1188055.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"887_CR39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.pcad.2020.04.004","volume":"63","author":"B Cybulska","year":"2020","unstructured":"Cybulska B, Klosiewicz-Latoszek L, Penson PE, Banach M. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery? Prog Cardiovasc Dis. 2020;63:219\u201327. https:\/\/doi.org\/10.1016\/j.pcad.2020.04.004.","journal-title":"Prog Cardiovasc Dis"},{"issue":"9","key":"887_CR40","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.clinthera.2019.06.002","volume":"41","author":"HO Santos","year":"2019","unstructured":"Santos HO, Kones R, Rumana U, Earnest CP, Izidoro LFM, Macedo RCO. Lipoprotein(a): current evidence for a physiologic role and the effects of nutraceutical strategies. Clin Ther. 2019;41(9):1780\u201397. https:\/\/doi.org\/10.1016\/j.clinthera.2019.06.002.","journal-title":"Clin Ther"},{"issue":"10","key":"887_CR41","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1080\/10408398.2016.1272045","volume":"58","author":"P Penson","year":"2018","unstructured":"Penson P, Serban MC, Ursoniu S, Banach M. Lipid, Blood Pressure Meta-analysis Collaboration G. Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review. Crit Rev Food Sci Nutr. 2018;58(10):1706\u201314. https:\/\/doi.org\/10.1080\/10408398.2016.1272045.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"1","key":"887_CR42","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/eurheartj\/ehz775","volume":"41","author":"M Banach","year":"2020","unstructured":"Banach M, Penson PE. Statins and Lp(a): do not make perfect the enemy of excellent. Eur Heart J. 2020;41(1):190\u20131. https:\/\/doi.org\/10.1093\/eurheartj\/ehz775.","journal-title":"Eur Heart J"},{"key":"887_CR43","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2019","unstructured":"Tsimikas S, Gordts P, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2019;41:2275\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehz310.","journal-title":"Eur Heart J"},{"issue":"9943","key":"887_CR44","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/s0140-6736(14)61212-5","volume":"384","author":"The Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2014","unstructured":"The Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384(9943):591\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(14)61212-5.","journal-title":"Lancet"},{"key":"887_CR45","volume-title":"Cellular pathology","author":"R Virchow","year":"1858","unstructured":"Virchow R. Cellular pathology. London: John Churchill; 1858."},{"issue":"23","key":"887_CR46","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","volume":"54","author":"P Libby","year":"2009","unstructured":"\u2022\u2022 Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on A. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129\u201338. https:\/\/doi.org\/10.1016\/j.jacc.2009.09.009The results of the CANTOS trial, presented in this paper, provide the first strong evidence to support the concept of \u201cresidual inflammatory risk\u201d for CVD in humans.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"887_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115\u201326. https:\/\/doi.org\/10.1056\/NEJM199901143400207.","journal-title":"N Engl J Med"},{"issue":"12","key":"887_CR48","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"issue":"8","key":"887_CR49","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1809798.","journal-title":"N Engl J Med"},{"issue":"26","key":"887_CR50","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1912388.","journal-title":"N Engl J Med"},{"issue":"6","key":"887_CR51","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1517\/14740338.2015.1039980","volume":"14","author":"M Banach","year":"2015","unstructured":"Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015;14(6):935\u201355. https:\/\/doi.org\/10.1517\/14740338.2015.1039980.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"887_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2015.49807","volume":"11","author":"M Banach","year":"2015","unstructured":"Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1\u201323. https:\/\/doi.org\/10.5114\/aoms.2015.49807.","journal-title":"Arch Med Sci"},{"issue":"7 Suppl","key":"887_CR53","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","volume":"32","author":"GB Mancini","year":"2016","unstructured":"Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group update (2016). Can J Cardiol. 2016;32(7 Suppl):S35\u201365. https:\/\/doi.org\/10.1016\/j.cjca.2016.01.003.","journal-title":"Can J Cardiol"},{"issue":"11","key":"887_CR54","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","volume":"69","author":"MC Serban","year":"2017","unstructured":"Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11):1386\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.036.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"887_CR55","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/jcsm.12344","volume":"9","author":"PE Penson","year":"2018","unstructured":"\u2022 Penson PE, GBJ M, Toth PP, Martin SS, Watts GF, Sahebkar A, et al. Introducing the \u201cDrucebo\u201d effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9(6):1023\u201333. https:\/\/doi.org\/10.1002\/jcsm.12344This study estimates the extent to which adverse effects of statin therapy can be attributed to patient expectation \u201cDrucebo effect\u201d rather than pharmacological effects.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"887_CR56","doi-asserted-by":"publisher","unstructured":"Penson P, Toth P, Mikhailidis D, Ezhov M, Fras Z, Mitchenko O et al. P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel. European Heart Journal. 2019;40(Supplement_1). https:\/\/doi.org\/10.1093\/eurheartj\/ehz747.0310.","DOI":"10.1093\/eurheartj\/ehz747.0310"},{"key":"887_CR57","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.atherosclerosissup.2019.08.023","volume":"39","author":"M Banach","year":"2019","unstructured":"Banach M, Bruckert E, Descamps OS, Ellegard L, Ezhov M, Foger B, et al. The role of red yeast rice (RYR) supplementation in plasma cholesterol control: a review and expert opinion. Atheroscler Suppl. 2019;39:e1\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2019.08.023.","journal-title":"Atheroscler Suppl"},{"key":"887_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2019.02.028","volume":"143","author":"F Fogacci","year":"2019","unstructured":"Fogacci F, Banach M, Mikhailidis DP, Bruckert E, Toth PP, Watts GF, et al. Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019;143:1\u201316. https:\/\/doi.org\/10.1016\/j.phrs.2019.02.028.","journal-title":"Pharmacol Res"},{"issue":"17","key":"887_CR59","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1080\/14656566.2018.1532501","volume":"19","author":"B Franczyk","year":"2018","unstructured":"Franczyk B, Gluba-Brzozka A, Jurkiewicz L, Penson P, Banach M, Rysz J. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy? Expert Opin Pharmacother. 2018;19(17):1857\u201365. https:\/\/doi.org\/10.1080\/14656566.2018.1532501.","journal-title":"Expert Opin Pharmacother"},{"key":"887_CR60","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"11","key":"887_CR61","doi-asserted-by":"publisher","first-page":"NP1","DOI":"10.1177\/2047487316653709","volume":"23","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016;23(11):NP1\u2013NP96. https:\/\/doi.org\/10.1177\/2047487316653709.","journal-title":"Eur J Prev Cardiol"},{"key":"887_CR62","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. https:\/\/doi.org\/10.1136\/bmj.j2099.","journal-title":"BMJ."},{"key":"887_CR63","unstructured":"National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification: Clinical guideline [CG181]. (2014, updated 2016)."},{"issue":"25","key":"887_CR64","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff","year":"2014","unstructured":"Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol. 2014;63(25):2935\u201359. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.005.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"887_CR65","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177\u2013232. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.010.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"887_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000068","volume":"1","author":"P Jeemon","year":"2011","unstructured":"Jeemon P, Prabhakaran D, Huffman MD, Ramakrishnan L, Goenka S, Thankappan KR, et al. Distribution of 10-year and lifetime predicted risk for cardiovascular disease in the Indian Sentinel Surveillance Study population (cross-sectional survey results). BMJ Open. 2011;1(1):e000068. https:\/\/doi.org\/10.1136\/bmjopen-2011-000068.","journal-title":"BMJ Open"},{"issue":"1","key":"887_CR67","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCOUTCOMES.109.869727","volume":"3","author":"AK Marma","year":"2010","unstructured":"Marma AK, Berry JD, Ning H, Persell SD, Lloyd-Jones DM. Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006. Circ Cardiovasc Qual Outcomes. 2010;3(1):8\u201314. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.109.869727.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"24","key":"887_CR68","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1161\/CIRCULATIONAHA.108.816694","volume":"119","author":"MJ Pencina","year":"2009","unstructured":"Pencina MJ, D\u2019Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119(24):3078\u201384. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.816694.","journal-title":"Circulation."}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00887-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-020-00887-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00887-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T23:58:19Z","timestamp":1631923099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-020-00887-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1007\/s11883-020-00887-z","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"10 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"<b><i>PEP<\/i><\/b> owns four shares in AstraZeneca PLC and has received honoraria and\/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Napp, and Sanofi; <b><i>MB<\/i><\/b>, speakers bureau: Abbott\/Mylan, Abbott Vascular, Actavis, AKCEA, Amgen, Biofarm, KRKA, MSD, Polpharma, Sanofi-Aventis, Servier, and Valeant; consultant to Abbott Vascular, AKCEA, Amgen, Daichii Sankyo, Esperion, Freia Pharmaceuticals, Lilly, MSD, Polfarmex, Resverlogix, and Sanofi-Aventis; and grants from Sanofi and Valeant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"67"}}